Close Menu

Pinpoint Genomics

In marketing its newly launched Pervenio lung cancer prognostic test, Life Technologies' sales force is targeting specialist thoracic surgeons and medical oncologists in 48 US states.

Life Technologies this week launched Pervenio Lung RS – a quantitative PCR-based assay for lung cancer prognosis that gauges the expression of 14 genes – through its CLIA lab in Sacramento, Calif.

This story has been updated from a previous version to include additional information about the QuantStudio Dx platform.

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

NEW YORK (GenomeWeb News) – Life Technologies said today that it has acquired Pinpoint Genomics and its early-stage non-small cell lung cancer test designed to help doctors identify early-stage patients at high risk for progression to late-stage disease.

By Tony Fong
NEW YORK (GenomeWeb News) – Genetic test maker Pinpoint Genomics has moved into commercialization phase with the launch of its first product, a prognostic test for non-small cell lung cancer.

Roche said this week that its Cobas CT/NG test for Chlamydia trachomatis and Neisseria gonorrhoeae infections has received 510(k) clearance from the US Food and Drug Administration.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.